argenx Q3 product sales rise 54% to $1.7 billion
- argenx reported third-quarter 2026 global product net sales of $1.7 billion, up 54% year over year and 13% sequentially.
- Net profit increased to $506 million from $344 million, while diluted earnings per share rose to $7.80 from $5.18.
- argenx expects approximately $4 billion in combined research, development and administrative expenses for 2026 while advancing multiple Phase 3 programs.
argenx (NASDAQ:ARGX) reported third-quarter 2026 global product net sales of $1.7 billion, up 54%, supported by continued VYVGART sales growth.
Sales increased 13% quarter over quarter, while net profit reached $506 million from $344 million and diluted earnings per share rose to $7.80.
Cash and current financial assets totaled $3.7 billion after approximately $2.1 billion in net acquisition payments for Forte Biosciences, while projected 2026 expenses reached $4 billion.
argenx expects Phase 3 empasiprubart results in December 2026 and plans a year-end VYVGART Hytrulo regulatory submission following positive ALKIVIA results.
The company is pursuing an additional registrational study in dermatomyositis and advancing FB102 into Phase 3 development for celiac disease.
argenx has also submitted an ocular myasthenia gravis application and expects an FDA decision on pediatric generalized myasthenia gravis in February 2027.
